Document is current
Any future updates will be listed below
-
Authors
Albers, Suki
Allen, Elizabeth C.
Bharti, Nikhil https://orcid.org/0000-0002-4068-0325
Davyt, Marcos https://orcid.org/0000-0001-6230-3654
Joshi, Disha
Perez-Garcia, Carlos G. https://orcid.org/0000-0003-1571-4850
Santos, Leonardo https://orcid.org/0000-0001-5650-8098
Mukthavaram, Rajesh
Delgado-Toscano, Miguel Angel https://orcid.org/0000-0001-9128-1511
Molina, Brandon
Kuakini, Kristen
Alayyoubi, Maher
Park, Kyoung-Joo Jenny https://orcid.org/0000-0002-9703-1975
Acharya, Grishma
Gonzalez, Jose A.
Sagi, Amit
Birket, Susan E.
Tearney, Guillermo J.
Rowe, Steven M.
Manfredi, Candela
Hong, Jeong S.
Tachikawa, Kiyoshi
Karmali, Priya
Matsuda, Daiki
Sorscher, Eric J. https://orcid.org/0000-0001-9341-3354
Chivukula, Pad https://orcid.org/0000-0001-6017-2267
Ignatova, Zoya https://orcid.org/0000-0002-9478-8825
- License Information
-
More Information
Article History
Received: 31 July 2021
Accepted: 25 April 2023
First Online: 31 May 2023
Competing interests
: Z.I., S.A., N.B. and M.D. are inventors on patents related to tRNA designs for PTC correction. Z.I. is also a scientific advisor for Tevard Biosciences. S.M.R. and G.J.T. are named on an unlicensed patent on the use of OCT for airway surface liquid measurements. S.M.R. is named on an unrelated patent on translational readthrough pharmacotherapy. E.J.S. is a non-voting board member of the Cystic Fibrosis Foundation. The LUNAR technology is proprietary to Arcturus Therapeutics. E.C.A., C.G.P.-G., R.M., B.M., K.K., M.A., K.J.-J.P., G.A., J.A.G., A.S., K.T., P.K., D.M. and P.C. are employees and have securities from Arcturus Therapeutics. The other authors declare no competing interests.
